119 related articles for article (PubMed ID: 26617887)
1. Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.
Huang H; Liu J; Meng Q; Niu G
Int J Clin Exp Pathol; 2015; 8(9):11537-42. PubMed ID: 26617887
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
Kreisholt J; Sorensen M; Jensen PB; Nielsen BS; Andersen CB; Sehested M
Br J Cancer; 1998 May; 77(9):1469-73. PubMed ID: 9652763
[TBL] [Abstract][Full Text] [Related]
3. Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Wang TL; Ren YW; Wang HT; Yu H; Zhao YX
Med Sci Monit; 2017 Feb; 23():984-993. PubMed ID: 28231233
[TBL] [Abstract][Full Text] [Related]
4. [Relationships among expressions of hTERT, MDR1, MRP mRNA, and C-myc protein in non-small cell lung cancer].
Li L; Xiong YY; Liu L; Chen TX; Yao XF; Wang YW
Ai Zheng; 2005 Jan; 24(1):53-7. PubMed ID: 15642200
[TBL] [Abstract][Full Text] [Related]
5. [Expression of multidrug resistance-associated protein gene in non-small cell lung cancer].
Xu M; Li J; Xia Q
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):268-70. PubMed ID: 11775850
[TBL] [Abstract][Full Text] [Related]
6. Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance.
Chen ZJ; Le HB; Zhang YK; Qian LY; Sekhar KR; Li WD
J Int Med Res; 2011; 39(5):1693-700. PubMed ID: 22117969
[TBL] [Abstract][Full Text] [Related]
7. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer.
Oshika Y; Nakamura M; Tokunaga T; Fukushima Y; Abe Y; Ozeki Y; Yamazaki H; Tamaoki N; Ueyama Y
Mod Pathol; 1998 Nov; 11(11):1059-63. PubMed ID: 9831202
[TBL] [Abstract][Full Text] [Related]
9. Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.
Zheng H; Li X; Chen C; Chen J; Sun J; Sun S; Jin L; Li J; Sun S; Wu X
Int J Nanomedicine; 2016; 11():5519-5529. PubMed ID: 27799773
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
11. [Expression of topoisomerase II alpha in human colorectal carcinoma and its significance].
Yang FD; Jia ZL
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Aug; 30(8):1959-61, 1964. PubMed ID: 20813715
[TBL] [Abstract][Full Text] [Related]
12. [Expression of multidrug resistance-associated protein in human non-small cell lung cancer].
Peng X; Feng F; Zhang W
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Nov; 22(11):655-8. PubMed ID: 11776518
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma].
Yu DQ; Yi YF
Ai Zheng; 2003 May; 22(5):496-9. PubMed ID: 12753710
[TBL] [Abstract][Full Text] [Related]
14. [Multidrug resistance and its relationship with neuroendocrine differentiation in non-small cell lung carcinoma].
Yu SP; Xiong YY; Tian SF
Zhonghua Jie He He Hu Xi Za Zhi; 2003 Mar; 26(3):165-8. PubMed ID: 12816683
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.
Wright SR; Boag AH; Valdimarsson G; Hipfner DR; Campling BG; Cole SP; Deeley RG
Clin Cancer Res; 1998 Sep; 4(9):2279-89. PubMed ID: 9748150
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
17. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
18. Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression.
Adachi M; Taki T; Konishi T; Huang CI; Higashiyama M; Miyake M
J Clin Oncol; 1998 Apr; 16(4):1397-406. PubMed ID: 9552043
[TBL] [Abstract][Full Text] [Related]
19. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Meng H; Chen R; Li W; Xu L; Xu L
Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
[TBL] [Abstract][Full Text] [Related]
20. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
